全球僵直性脊椎炎市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球僵直性脊椎炎市場預計將從2025年的71.1億美元成長至2034年的127.1億美元，2026年至2034年的複合年成長率（CAGR）為6.66%。全球僵直性脊椎炎市場持續穩定成長，主要得益於診斷率的提高和人們對發炎性自體免疫疾病認知的增強。影像技術的進步和早期篩檢方案的引入使得僵直性脊椎炎的早期發現成為可能，尤其是在年輕患者群體中。慢性背痛負擔的加重和遺傳易感性等因素進一步推動了已開發國家和新興國家醫療保健系統對標靶生物製藥和先進療法的需求。

成長要素包括TNF抑制劑和IL-17抑制劑等生物製藥的日益普及，以及已開發國家健保覆蓋範圍的擴大。製藥公司正大力投資研發，以推出療效和安全性更高的新一代生物製藥。此外，患者支持活動和宣傳宣傳活動提高了公眾對該疾病的認知，從而加速了治療的推廣，並擴大了目標患者群體。

預計未來市場將保持強勁成長，主要得益於生物相似藥的上市、精準醫療方法的應用以及免疫學研究的進展。在新興市場，醫療基礎設施的改善和醫療支出的成長預計將顯著促進市場成長。將數位醫療技術應用於遠端監測和藥物依從性追蹤，將進一步改善患者預後，並為僵直性脊椎炎市場的長期持續擴張奠定基礎。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球僵直性脊椎炎市場：依藥物類型分類

• 市場分析、洞察與預測
• 非類固醇消炎劑（NSAIDs）
• 緩解疾病抗風濕藥物（DMARDs）
• TNF抑制劑
• 皮質類固醇
• 其他

第5章：全球僵直性脊椎炎市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 腸外

第6章 全球僵直性脊椎炎市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球僵直性脊椎炎市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • AbbVie Inc
  • Amgen Inc
  • Biocon Limited
  • Bristol-Myers Squibb Company
  • Celltrion Inc
  • Cipla Inc
  • Eli Lilly And Company
  • Emcure Pharmaceuticals
  • F. Hoffmann-La Roche Ltd
  • Jiangsu Hengrui Pharmaceuticals Co.Ltd
  • Intas Pharmaceuticals Ltd
  • Johnson & Johnson ServicesInc
  • Merck & Co.Inc
  • Novartis AG
  • Pfizer Inc
  • Regeneron PharmaceuticalsInc
  • Samsung Bioepis Co.Ltd
  • Sandoz International GmbH
  • Sanofi
  • Suzhou Zelgen Biopharmaceuticals Co.Ltd
  • Takeda Pharmaceutical Company Limited
  • Torrent Pharmaceuticals Ltd

The global ankylosing spondylitis market size is expected to reach USD 12.71 Billion in 2034 from USD 7.11 Billion in 2025, growing at a CAGR of 6.66 during 2026-2034.The Global Ankylosing Spondylitis Market is experiencing steady expansion driven by rising diagnosis rates and increasing awareness of inflammatory autoimmune disorders. Improved imaging technologies and earlier screening protocols are enabling timely identification of ankylosing spondylitis, particularly among younger populations. The growing burden of chronic back pain and genetic predisposition factors are further contributing to demand for targeted biologics and advanced therapeutic interventions across developed and emerging healthcare systems.

Key growth drivers include the strong adoption of biologic therapies such as TNF inhibitors and IL-17 inhibitors, alongside expanding reimbursement coverage in developed economies. Pharmaceutical companies are investing heavily in research and development to introduce next-generation biologics with improved efficacy and safety profiles. Additionally, patient advocacy initiatives and educational campaigns are improving disease awareness, thereby accelerating treatment uptake and expanding the addressable patient pool.

Looking ahead, the market is poised for robust growth fueled by biosimilar launches, precision medicine approaches, and advancements in immunology research. Emerging markets are expected to contribute significantly due to improving healthcare infrastructure and rising healthcare expenditure. Digital health integration for remote monitoring and adherence tracking will further enhance patient outcomes, positioning the ankylosing spondylitis market for sustained long-term expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug Type

• Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
• Disease-modifying Anti-rheumatic Drugs (DMARDs)
• TNF Inhibitors
• Corticosteroids
• Others

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• AbbVie Inc., Amgen Inc., Biocon Limited, Bristol-Myers Squibb Company, Celltrion Inc., Cipla Inc., Eli Lilly and Company, Emcure Pharmaceuticals, F. Hoffmann-La Roche Ltd., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Intas Pharmaceuticals Ltd., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sandoz International GmbH, Sanofi, Suzhou Zelgen Biopharmaceuticals Co., Ltd., Takeda Pharmaceutical Company Limited, Torrent Pharmaceuticals Ltd.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Disease-modifying Anti-rheumatic Drugs (DMARDs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. TNF Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Type
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Type
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Type
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Type
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Type
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ANKYLOSING SPONDYLITIS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 AbbVie Inc
  • 9.2.2 Amgen Inc
  • 9.2.3 Biocon Limited
  • 9.2.4 Bristol-Myers Squibb Company
  • 9.2.5 Celltrion Inc
  • 9.2.6 Cipla Inc
  • 9.2.7 Eli Lilly And Company
  • 9.2.8 Emcure Pharmaceuticals
  • 9.2.9 F. Hoffmann-La Roche Ltd
  • 9.2.10 Jiangsu Hengrui Pharmaceuticals Co.Ltd
  • 9.2.11 Intas Pharmaceuticals Ltd
  • 9.2.12 Johnson & Johnson ServicesInc
  • 9.2.13 Merck & Co.Inc
  • 9.2.14 Novartis AG
  • 9.2.15 Pfizer Inc
  • 9.2.16 Regeneron PharmaceuticalsInc
  • 9.2.17 Samsung Bioepis Co.Ltd
  • 9.2.18 Sandoz International GmbH
  • 9.2.19 Sanofi
  • 9.2.20 Suzhou Zelgen Biopharmaceuticals Co.Ltd
  • 9.2.21 Takeda Pharmaceutical Company Limited
  • 9.2.22 Torrent Pharmaceuticals Ltd